Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$318.3 million.

  • Takeda Pharmaceutical's Net Cash Flow rose 8752.09% to -$318.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year decrease of 2632.97%. This contributed to the annual value of $585.0 million for FY2025, which is 1572.4% down from last year.
  • Takeda Pharmaceutical's Net Cash Flow amounted to -$318.3 million in Q4 2025, which was up 8752.09% from $2.2 billion recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Net Cash Flow ranged from a high of $5.0 billion in Q1 2021 and a low of -$2.9 billion during Q2 2021
  • For the 5-year period, Takeda Pharmaceutical's Net Cash Flow averaged around $313.7 million, with its median value being $122.6 million (2023).
  • Over the last 5 years, Takeda Pharmaceutical's Net Cash Flow had its largest YoY gain of 408195.35% in 2024, and its largest YoY loss of 131855.4% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Net Cash Flow stood at $970.4 million in 2021, then plummeted by 175.43% to -$732.0 million in 2022, then skyrocketed by 75.44% to -$179.8 million in 2023, then tumbled by 1318.55% to -$2.6 billion in 2024, then skyrocketed by 87.52% to -$318.3 million in 2025.
  • Its Net Cash Flow stands at -$318.3 million for Q4 2025, versus $2.2 billion for Q3 2025 and -$225.8 million for Q2 2025.